90 related articles for article (PubMed ID: 20156671)
1. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Hohla F; Buchholz S; Schally AV; Krishan A; Rick FG; Szalontay L; Papadia A; Halmos G; Koster F; Aigner E; Datz C; Seitz S
Cancer Lett; 2010 Aug; 294(1):35-42. PubMed ID: 20156671
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
Pozsgai E; Schally AV; Halmos G; Rick F; Bellyei S
Horm Metab Res; 2010 Oct; 42(11):781-6. PubMed ID: 20665426
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
4. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
[TBL] [Abstract][Full Text] [Related]
5. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Seitz S; Schally AV; Treszl A; Papadia A; Rick F; Szalontay L; Szepeshazi K; Ortmann O; Halmos G; Hohla F; Buchholz S
Anticancer Drugs; 2009 Aug; 20(7):553-8. PubMed ID: 19491659
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
[TBL] [Abstract][Full Text] [Related]
9. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
[TBL] [Abstract][Full Text] [Related]
10. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
[TBL] [Abstract][Full Text] [Related]
13. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
Szepeshazi K; Schally AV; Halmos G
Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells.
Quan ZW; Yue JN; Li JY; Qin YY; Guo RS; Li SG
Chemotherapy; 2008; 54(6):431-7. PubMed ID: 18824850
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
[TBL] [Abstract][Full Text] [Related]
16. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
18. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
Ghoul A; Serova M; Astorgues-Xerri L; Bieche I; Bousquet G; Varna M; Vidaud M; Phillips E; Weill S; Benhadji KA; Lokiec F; Cvitkovic E; Faivre S; Raymond E
Cancer Res; 2009 May; 69(10):4260-9. PubMed ID: 19417139
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine leukemic P388 and P388/R84 cells.
Ramachandran C; You W; Krishan A
Anticancer Res; 1997; 17(5A):3369-76. PubMed ID: 9413174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
